124.89
0.29%
0.36
Vorhandelsmarkt:
124.88
-0.01
-0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Dimensional Fund Advisors LP Has $40.35 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Is Sarepta Therapeutics, Inc. (SRPT) One of the Best Revenue Growth Stocks to Buy According to Analysts? - Insider Monkey
Is Sarepta Therapeutics, Inc. (SRPT) One of the Best Revenue Growth Stocks to Buy According to Analysts? - Yahoo Finance
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher - sharewise
Sarepta Therapeutics' SWOT analysis: broad elevidys label boosts stock outlook - Investing.com
7 Best Revenue Growth Stocks to Buy According to Analysts - Insider Monkey
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress - BioSpace
Dispute over Duchenne gene therapy highlights thorny access issues - STAT
Lighthouse Investment Partners LLC Invests $7.95 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
The Play On Sarepta Therapeutics (NASDAQ:SRPT) - Seeking Alpha
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress - StockTitan
Duchenne Muscular Dystrophy Treatment Market Will Accelerate - openPR
Point72 Hong Kong Ltd Acquires New Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Fred Alger Management LLC - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Avoro Capital Advisors LLC - MarketBeat
Exploring TeraWulf And Two Other High Growth Tech Stocks - Simply Wall St
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Profund Advisors LLC Buys 17,132 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Ensign Peak Advisors Inc - Defense World
Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options - MSN
Sarepta Therapeutics (SRPT): Soaring with Successful Therapies and Cash Flow Positivity - Yahoo Finance
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Forecasted to Post Q1 2026 Earnings of $2.75 Per Share - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Receives Neutral Rating from Cantor Fitzgerald - MarketBeat
Zacks Research Equities Analysts Boost Earnings Estimates for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Simplify Asset Management Inc. - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Receives "Outperform" Rating from Royal Bank of Canada - MarketBeat
Marvell co-founder Sehat Sutardja has died as industry mourns semiconductor visionary - DIGITIMES
Blair William & Co. IL Has $27.54 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Sehat Sutardja, semiconductor pioneer and Marvell co-founder, has died - Berkeley Engineering
Sacha Feinberg-Mngomezulu is the future of the Springboks, but don’t write off Manie Libbok just yet - IOL
Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options - Yahoo Finance
Blair William & Co. IL Increases Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
16 Best Mid Cap Growth Stocks To Buy Now - Insider Monkey
Sarepta Therapeutics Muscles Up In DMD Race - Seeking Alpha
Rassie unhappy with Sacha after ‘hiding’ injury - MSN
Sarepta Therapeutics (NASDAQ:SRPT) PT Raised to $188.00 at UBS Group - MarketBeat
Sofinnova Investments Inc. Decreases Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Investing in Sarepta Therapeutics (NASDAQ:SRPT) five years ago would have delivered you a 55% gain - Simply Wall St
Acadian Asset Management LLC Buys New Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics appoints new board member - Investing.com
Sarepta Therapeutics appoints new board member By Investing.com - Investing.com Canada
Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors - citybiz
Sarepta Therapeutics Expands Board, Welcomes New Director - TipRanks
Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors - Business Wire
Texas Permanent School Fund Corp Takes Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics, Inc. (SRPT): Among Hedge Funds’ Top Biotech Stock Picks - Insider Monkey
Sarepta Therapeutics, Inc. (SRPT): Among Hedge Funds’ Top Biotech Stock Picks - Yahoo Finance
Federated Hermes Inc. Sells 101,887 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 1.5% - MarketBeat
First Turn Management LLC Has $28.70 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
These 2 Biotech Stocks Are Set to Soar - The Motley Fool
Gene Therapy Market Set for 19% CAGR Surge, Reaching USD 38.34 Billion by 2031 | SkyQuest Technology - Benzinga
SRPT Makes Notable Cross Below Critical Moving Average - Nasdaq
10 Largest Biotech Hedge Funds and Their Top Stock Picks - Insider Monkey
Natixis Advisors LLC Takes $1.92 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
TD Asset Management Inc Cuts Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Advanced Therapy Based on Gene Production Market Segments, - openPR
New Mexico Educational Retirement Board Takes $3.03 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics, Inc. (SRPT): This Biotech Stock Should Be On Your Radar - Yahoo Finance
Real-World Experience With Duchenne Muscular Dystrophy Gene Therapy - CGTLive™
Unveiling 26 Analyst Insights On Sarepta Therapeutics - Benzinga
Relative Strength Alert For Sarepta Therapeutics - Nasdaq
Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Reaffirmed by Royal Bank of Canada - MarketBeat
Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report? - Yahoo Finance
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):